The UK reached an agreement with the US for zero tariffs on all medicines exported to the US for at least three years.[1][5] In return, British pharmaceutical companies have pledged to invest more in the US and create more jobs there.[1] The deal comes after warnings that US pharmaceutical firms will close their UK operations if the UK's NHS health system does not pay more for the drugs.[1] The government in London has agreed to invest around 25% more in new medicines and effective treatments.[1] This is the first significant increase in such spending in more than two decades.[1] This transatlantic trade policy supports the UK's pharmaceutical outlook despite a lackluster FDI environment in UK life sciences.[1]